All‐cause mortality · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes all‐cause mortality compared with no intervention (very low certainty).
1 finding from 1 review
Upper gastrointestinal bleeding · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes upper gastrointestinal bleeding compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events and liver‐related morbidity: incidence of congestive hypertensive gastropathy · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events and liver‐related morbidity: incidence of gastric varices · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events and liver‐related morbidity: incidence of bleeding from gastric varices · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes serious adverse events and liver‐related morbidity: incidence of… compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Oesophageal variceal bleeding · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes oesophageal variceal bleeding compared with no intervention (very low certainty).
1 finding from 1 review
Non‐serious adverse events · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
1 finding from 1 review
Intervention not reported
Sclerotherapy(1 RCT, 85 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
It is very uncertain whether the intervention changes sclerotherapy(1 RCT, 85 participants) (very low certainty).
1 finding from 1 review
OR 0.55 [0, 272.05]
Studies not reported
Very low
Intervention not reported
Sclerotherapy(No direct RCT) · people with liver cirrhosis and oesophageal varices with no history of bleeding
It is very uncertain whether the intervention changes sclerotherapy(No direct RCT) (very low certainty).
1 finding from 1 review
OR 1.19 [0.02, 80.24]
Studies not reported
Very low
Intervention not reported
Sclerotherapy(2 RCTs, 90 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Sclerotherapy(1 RCT, 141 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
It is very uncertain whether the intervention changes sclerotherapy(1 RCT, 141 participants) (very low certainty).
1 finding from 1 review
HR 0.91 [0.44, 1.95]
Studies not reported
Very low
Intervention not reported
Beta‐blockers + sclerotherapy(1 RCT, 141 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
It is very uncertain whether the intervention changes beta‐blockers + sclerotherapy(1 RCT, 141 participants) (very low certainty).
1 finding from 1 review
HR 0.92 [0.41, 2.08]
Studies not reported
Very low
Intervention not reported
Sclerotherapy(3 RCTs, 175 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
It is very uncertain whether the intervention changes sclerotherapy(3 RCTs, 175 participants) (very low certainty).
1 finding from 1 review
HR 1.02 [0.33, 3.27]
Studies not reported
Very low
Intervention not reported
Sclerotherapy(5 RCTs, 320 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
It is very uncertain whether the intervention changes sclerotherapy(5 RCTs, 320 participants) (very low certainty).
1 finding from 1 review
HR 1.35 [0.95, 1.92]
Studies not reported
Very low
Intervention not reported
Beta‐blockers + sclerotherapy(2 RCTs, 167 participants) · people with liver cirrhosis and oesophageal varices with no history of bleeding
The intervention may leads to higher beta‐blockers + sclerotherapy(2 RCTs, 167 participants) (low certainty).
1 finding from 1 review
HR 2.08 [1.03, 4.08]
Studies not reported
Low
Intervention not reported
Sclerotherapy plus Variceal band ligation(No direct RCT) · people with liver cirrhosis and previous oesophageal variceal bleeding
The intervention showed no clear difference in sclerotherapy plus Variceal band ligation(No direct RCT) (low certainty).
1 finding from 1 review
HR 0.78 [0.35, 1.76]
Studies not reported
Low
Intervention not reported
Sclerotherapy plus Nitrates(1 RCT; 76 participants) · people with liver cirrhosis and previous oesophageal variceal bleeding
The intervention probably leads to lower sclerotherapy plus Nitrates(1 RCT; 76 participants) (moderate certainty).
1 finding from 1 review
HR 0.19 [0.02, 0.86]
Studies not reported
Moderate
Intervention not reported
Beta‐blockers plus Sclerotherapy(No direct RCT) · people with liver cirrhosis and previous oesophageal variceal bleeding
It is very uncertain whether the intervention changes beta‐blockers plus Sclerotherapy(No direct RCT) (very low certainty).
1 finding from 1 review
OR 1.29 [0.28, 5.7]
Studies not reported
Very low
Intervention not reported
Beta‐blockers plus Sclerotherapy(2 RCTs; 71 participants) · people with liver cirrhosis and previous oesophageal variceal bleeding
The intervention showed no clear difference in beta‐blockers plus Sclerotherapy(2 RCTs; 71 participants) (low certainty).
1 finding from 1 review
OR 1.46 [0.36, 6.06]
Studies not reported
Low